

NEW AMENDMENT TO THE OA/ AMGEN MULTI-PRODUCT AGREEMENT



Aranesp[®], Neulasta[™] and Neupogen[®]

Oncology Associates is pleased to announce that OA Members will earn an improved rebate for all Amgen contracted product purchases made from June 1, 2003 to July 15, 2004. Members will continue to have access to OA's group agreement off-invoice discounts for all contracted Amgen products as well as a possible supplemental rebate (Amgen Shared Commitment Program) if signed and returned to Amgen by May 30, 2003.

As a member of OA, the new Physician Clinic Agreement (PCA) will be automatically applied to your Aranesp[®] (darbepoetin alfa), Neulasta[™] (pegfilgrastim), and Neupogen[®] (Filgrastim) purchases.

"Amgen has clearly demonstrated its commitment to our members with this latest enhancement to our current agreement," says Joe Lewarski, OA's Chief Operating Officer and Co-Founder.

OA encourages you to work with your local Amgen sales representative who can provide detailed information about your Physician Clinic Agreement and, if eligible, the Amgen Shared Commitment Program.

OA thanks you for your support and participation on this valuable agreement with Amgen. Contact Oncology Associates with any questions regarding this contract at **888-732-7352**.



OA SIGNS AGREEMENT WITH GENSIA SICOR FOR VINOURELBINE

Oncology Associates is pleased to announce a new pricing agreement with Gensia Sicor (soon to be known as "Sicor") for Vinorelbine Tartrate Injection. Vinorelbine Tartrate is a semi-synthetic vinca alkaloid with anti-tumor activity. Each vial contains 10 mg (1-mL vial) or 50 mg (5-mL vial) of Vinorelbine Tartrate in water for intravenous administration.

"We are pleased about the opportunity to contract with OA and its membership and look forward to a long relationship together," says Cam Bivens, Senior National Account Manager for Gensia Sicor.

According to Brent Evans, Executive Vice President & General Manager for Oncology Associates, "The addition of Gensia Sicor as a partner supplements OA's already robust portfolio of products and provides more variety for the future needs of our physicians."

Gensia Sicor, Inc. is a vertically integrated, multinational pharmaceutical company that focuses on generic finished dosage injectable pharmaceuticals, active pharmaceutical ingredients, or APIs, and generic biopharmaceuticals.

NDC #	PRODUCT NAME	DESCRIPTION	SIZE	PACKAGE SIZE
4182-01	Vinorelbine Tartrate Injection	10 mg/mL	1 mL	1
4183-01	Vinorelbine Tartrate Injection	50 mg/mL	5 mL	1